Pay in 4 interest-free payments of $5.63 Learn more
Ships within 48 hours · Estimated delivery Sep 24 - Sep 29
Saxenda (active ingredient: liraglutide) subcutaneous injection Initial FDA Approval: 2014 (liraglutide approved in 2010) Side Effect Update Date: May 28, 2025 Medication Description: For chronic weight management Updated Side Effects/Safety Information: A new warning section on Severe Gastrointestinal Adverse Reactions. An additional warning about the risk of serious kidney injury caused by dehydration due to gastrointestinal adverse effects like diarrhea and vomiting
621 TRPA1 antagonist ISC 17536: ISC 17536 is a potent and selective antagonist targeting TRPA1
Scientific American (24 November 2014)
Susthota delivery system improve korle valo hoy
US$ 24.93
US$ 22.18
US$ 27.08
US$ 28.79
US$ 26.89
